Safety and Immunogenicity of Revaccination With Influenza Vaccine in Healthy Adult Subjects Aged 18 to 64 Years Who Were Previously Vaccinated With Fluzone ID or Fluzone IM [EXTENSION OF 700038401]
Latest Information Update: 04 Apr 2014
At a glance
- Drugs Influenza virus vaccine (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Sanofi
- 19 Sep 2013 Results published in Vaccine.
- 10 Aug 2013 New trial record